TRDA insider transactions
Entrada Therapeutics Inc. (TRDA) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for TRDA
- Large owner Mpm Bioventures 2018, L.P. sold $1,905,768 worth of shares (259,837 units at $7.33) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Large owner Mpm Bioventures 2014, L.P. sold $1,905,768 worth of shares (259,837 units at $7.33) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Large owner Mpm Bioventures 2018, L.P. sold $617,379 worth of shares (86,482 units at $7.14) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Large owner Mpm Bioventures 2014, L.P. sold $617,379 worth of shares (86,482 units at $7.14) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President, Research & Develop. Sethuraman Natarajan covered exercise/tax liability with 2,079 shares, decreasing direct ownership by 0.96% to 214,238 units (SEC Form 4) to cover withholding tax4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- CEO Doshi Dipal covered exercise/tax liability with 8,724 shares, decreasing direct ownership by 2% to 517,290 units (SEC Form 4) to satisfy withholding tax4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President & COO Dowden Nathan J covered exercise/tax liability with 2,528 shares, decreasing direct ownership by 1% to 196,060 units (SEC Form 4) to cover taxes4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Chief Financial Officer Wentworth Kory James covered exercise/tax liability with 1,733 shares, decreasing direct ownership by 1% to 117,277 units (SEC Form 4) (for tax liability)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Large owner Mpm Bioventures 2018, L.P. sold $615,777 worth of shares (86,914 units at $7.08) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Large owner Mpm Bioventures 2014, L.P. sold $615,777 worth of shares (86,914 units at $7.08) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Large owner Mpm Bioventures 2014, L.P. sold $461,546 worth of shares (62,714 units at $7.36) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Large owner Mpm Bioventures 2018, L.P. sold $461,546 worth of shares (62,714 units at $7.36) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Director Parmar Kush sold $1,078,937 worth of shares (155,255 units at $6.95) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Large owner 5am Ventures V, L.P. sold $431,829 worth of shares (62,811 units at $6.88) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Large owner 5am Ventures V, L.P. sold $807,027 worth of shares (116,474 units at $6.93) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Director Parmar Kush sold $807,027 worth of shares (116,474 units at $6.93) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Parmar Kush4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Kim Peter S4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Chapman Gina4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Radhakrishnan Maha4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Thistle Mary4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Zeiher Bernhardt G4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Director Zeiher Bernhardt G bought $29,316 worth of shares (5,000 units at $5.86) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President, Research & Develop. Sethuraman Natarajan sold $398,810 worth of shares (25,907 units at $15.39) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 216,317 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President & COO Dowden Nathan J exercised 15,000 shares at a strike of $1.74 and sold $229,953 worth of shares (15,000 units at $15.33) as part of a pre-agreed trading plan (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Wentworth Kory James4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Entrada Therapeutics Inc.4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Entrada Therapeutics Inc.4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Chief Financial Officer Wentworth Kory James sold $97,892 worth of shares (7,988 units at $12.25), decreasing direct ownership by 5% to 137,987 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- CEO Doshi Dipal was granted 139,400 shares and covered exercise/tax liability with 29,050 shares, increasing direct ownership by 27% to 526,014 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Chief Financial Officer Wentworth Kory James was granted 44,600 shares and covered exercise/tax liability with 8,651 shares, increasing direct ownership by 33% to 145,975 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President & COO Dowden Nathan J was granted 55,800 shares and covered exercise/tax liability with 21,261 shares, increasing direct ownership by 19% to 213,598 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President, Research & Develop. Sethuraman Natarajan covered exercise/tax liability with 11,475 shares and was granted 55,800 shares, increasing direct ownership by 22% to 242,224 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Chief Financial Officer Wentworth Kory James sold $88,932 worth of shares (8,910 units at $9.98), decreasing direct ownership by 7% to 110,026 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Large owner Baker Bros. Advisors Lp bought $261,846 worth of shares (28,867 units at $9.07) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Director Parmar Kush sold $1,760,000 worth of shares (200,000 units at $8.80) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Large owner 5am Ventures V, L.P. sold $1,760,000 worth of shares (200,000 units at $8.80) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Large owner Baker Bros. Advisors Lp bought $1,352,587 worth of shares (178,044 units at $7.60) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- CEO Doshi Dipal covered exercise/tax liability with 8,723 shares, decreasing direct ownership by 2% to 415,664 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President & COO Dowden Nathan J covered exercise/tax liability with 1,746 shares, decreasing direct ownership by 0.97% to 179,059 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President, Research & Develop. Sethuraman Natarajan covered exercise/tax liability with 1,760 shares, decreasing direct ownership by 0.88% to 197,899 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Chief Financial Officer Wentworth Kory James covered exercise/tax liability with 1,734 shares, decreasing direct ownership by 1% to 118,936 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Director Parmar Kush sold $202,554 worth of shares (27,000 units at $7.50) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Large owner 5am Ventures V, L.P. sold $202,554 worth of shares (27,000 units at $7.50) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Director Parmar Kush sold $866,632 worth of shares (125,000 units at $6.93) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Large owner 5am Ventures V, L.P. sold $866,632 worth of shares (125,000 units at $6.93) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Amendment: Director Kim Peter S bought $731,682 worth of shares (50,000 units at $14.63), increasing direct ownership by 74% to 117,412 units (SEC Form 4)4/A - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Parmar Kush4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Kim Peter S4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Thistle Mary4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Zeiher Bernhardt G4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Chapman Gina4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 4 filed by Director Radhakrishnan Maha4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SEC Form 3 filed by new insider Radhakrishnan Maha3 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Chief Financial Officer Wentworth Kory James exercised 11,134 shares at a strike of $2.10, increasing direct ownership by 10% to 120,670 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Chief Financial Officer Wentworth Kory James sold $19,035 worth of shares (1,784 units at $10.67), decreasing direct ownership by 2% to 109,536 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- CEO Doshi Dipal was granted 116,200 shares and covered exercise/tax liability with 17,566 shares, increasing direct ownership by 30% to 424,387 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- Chief Financial Officer Wentworth Kory James was granted 42,400 shares and covered exercise/tax liability with 4,929 shares, increasing direct ownership by 51% to 111,320 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President & COO Dowden Nathan J was granted 60,800 shares and covered exercise/tax liability with 5,144 shares, increasing direct ownership by 44% to 180,805 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- President, Research & Develop. Sethuraman Natarajan was granted 60,800 shares and covered exercise/tax liability with 6,138 shares, increasing direct ownership by 38% to 199,659 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)